Ian Clements is CFO at Mirum Pharmaceuticals, Inc. (MIRM). They have made 5 open-market trades across 1 company since 2019, most recently 2022-11-10.
CIK 0001780080
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $142K since 2019, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MIRM | 30,011 | $2.9M |
Shares reported on the most recent Form 4, priced at the 2022-11-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MIRM | BUY | 2021-11-24 | 2021-11-29 | $14.14 | $21K | +5.5% | +16.0% | +74.8% |
| MIRM | SELL | 2021-10-01 | 2021-10-01 | $19.26 | $30K | -12.1% | -15.6% | -18.3% |
| MIRM | BUY | 2020-12-23 | 2020-12-28 | $18.61 | $46K | +4.1% | -5.2% | +1.1% |
| MIRM | BUY | 2020-12-23 | 2021-03-08 | $18.65 | $30K | +10.1% | +9.4% | -9.7% |
| MIRM | BUY | 2019-09-06 | 2019-09-10 | $11.51 | $46K | -11.0% | -9.2% | -7.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.